Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05410301 | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | N/A | withdrawn | Jun 8, 2022 | Varun Monga, MD | PI leaving institution | Other (stated, no rule matched) |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Phase 1 | terminated | Oct 22, 2018 | Clinica Universidad de Navarra, Universidad de Navarra | Break of stock | Other (stated, no rule matched) |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03956706 | Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas | N/A | withdrawn | May 21, 2019 | Northwell Health | no partipants enrolled and investigator left the institution | Investigator |
| NCT01933815 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same… | Phase 1 / Phase 2 | suspended | Sep 2, 2013 | Cortice Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma(FOLAGLI) | Phase 1 | terminated | Oct 4, 2012 | Institut Cancerologie de l'Ouest | changing the standard of care | Other (stated, no rule matched) |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | Phase 1 | terminated | Jan 27, 2016 | Daniel Landi | Study funding ended | Funding |
| NCT03430791 | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab… | Phase 2 | terminated | Feb 13, 2018 | Baptist Health South Florida | Study Investigator/Sponsor decided to end enrollment earlier. | Investigator |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With…(KING) | Phase 2 | terminated | Nov 18, 2013 | Karyopharm Therapeutics Inc | Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2… | Sponsor / business decision |
| NCT02769806 | Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma | — | terminated | May 12, 2016 | University of Wisconsin, Madison | funding | Funding |
| NCT01822275 | Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and…(GCC 1224) | Phase 2 | terminated | Apr 2, 2013 | University of Maryland, Baltimore | Poor accrual | Enrollment / accrual |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | Phase 1 / Phase 2 | terminated | Apr 18, 2017 | Brown University | lack of response to study therapy | Other (stated, no rule matched) |
| NCT04895553 | Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism… | — | terminated | May 20, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | lack of funds. Only 1 patient was enrolled | Enrollment / accrual |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | Early Phase 1 | withdrawn | Aug 24, 2021 | Emory University | Per the PI-slow accrual | Enrollment / accrual |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT02641782 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial(NB2013-HR) | Phase 2 | terminated | Dec 29, 2015 | University of Cologne | Antibody supply was discontinued by United Therapeutics Corporation. | Drug supply |
| NCT01954576 | NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | N/A | terminated | Oct 7, 2013 | University of Florida | Poor accrual; Avastin refractory patients not feasible given treatment paradigm in these patients. | Enrollment / accrual |
| NCT02880111 | Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa(DMBT1) | — | terminated | Aug 26, 2016 | University Hospital, Lille | only one patient was included | Other (stated, no rule matched) |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | Phase 1 / Phase 2 | withdrawn | Aug 28, 2018 | Oblato, Inc. | Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This Study… | Other (stated, no rule matched) |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in… | Phase 2 | terminated | Aug 31, 2016 | Indiana University | Failure to meet accrual goals. | Enrollment / accrual |
| NCT04776980 | Multimodality MRI and Liquid Biopsy in GBM | Early Phase 1 | withdrawn | Mar 2, 2021 | Abramson Cancer Center at Penn Medicine | PI decision to close study | Other (stated, no rule matched) |
| NCT03209869 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded… | Phase 1 | withdrawn | Jul 6, 2017 | University of Wisconsin, Madison | resources limited due to COVID-19 | COVID-19 / pandemic |
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin… | Phase 2 | withdrawn | Jun 1, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent… | Phase 1 | withdrawn | Dec 16, 2019 | University of Rochester | One of the drugs for the study is not commercially available. | Other (stated, no rule matched) |
| NCT03856099 | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | Phase 2 | terminated | Feb 27, 2019 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent… | Phase 2 | terminated | Jan 16, 2017 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent…(CYNK001GBM01) | Phase 1 | terminated | Jul 28, 2020 | Celularity Incorporated | Business decision. | Sponsor / business decision |
| NCT04926168 | 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT… | — | withdrawn | Jun 15, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | lack of funds | Funding |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial… | Phase 1 / Phase 2 | terminated | Jun 24, 2013 | Weill Medical College of Cornell University | The study was prematurely closed in December 2021 due to low accrual. | Enrollment / accrual |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and… | Phase 2 | terminated | Nov 1, 2018 | National Cancer Institute (NCI) | The pharmaceutical company decided to close their program evaluating the study agent, Marizomib. | Sponsor / business decision |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors… | Phase 1 / Phase 2 | withdrawn | Mar 19, 2020 | Y-mAbs Therapeutics | Business priorities | Sponsor / business decision |
| NCT02663271 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | Phase 2 | terminated | Jan 26, 2016 | University of Florida | stagnant enrollment | Enrollment / accrual |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With… | Phase 1 / Phase 2 | terminated | May 28, 2007 | Boston Scientific Corporation | Sponsor business decision, not based on safety or efficacy data | Safety / toxicity |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | Phase 1 | terminated | Aug 12, 2016 | Eric Thompson, M.D. | Funding | Funding |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in… | Phase 1 / Phase 2 | terminated | Apr 30, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss in funding. | Funding |
| NCT04460495 | Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI | N/A | terminated | Jul 7, 2020 | Jonsson Comprehensive Cancer Center | insufficient accrual | Enrollment / accrual |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | Phase 2 | terminated | Aug 22, 2018 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT04219475 | Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients(PROPHETIC) | — | suspended | Jan 7, 2020 | OncoHost Ltd. | Priority changes of the company | Sponsor / business decision |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's… | Phase 1 / Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT02163356 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant…(SPOC2013-001) | Phase 1 | terminated | Jun 13, 2014 | South Plains Oncology Consortium | drug supply | Drug supply |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients… | Phase 1 / Phase 2 | withdrawn | Aug 22, 2019 | Genexine, Inc. | Canceled by the sponsor | Other (stated, no rule matched) |
| NCT01925573 | Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation… | N/A | terminated | Aug 19, 2013 | University of Maryland, Baltimore | Poor accrual | Enrollment / accrual |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | Phase 1 | terminated | Aug 29, 2019 | Klinikum Stuttgart | low recruitment | Enrollment / accrual |
| NCT01331616 | Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab | Early Phase 1 | withdrawn | Apr 8, 2011 | West Penn Allegheny Health System | not stated | Not stated |
| NCT02212574 | Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt… | Early Phase 1 | terminated | Aug 8, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Participant relapses led to abrupt stop of study. | Other (stated, no rule matched) |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in… | Phase 1 | terminated | Feb 5, 2018 | Washington University School of Medicine | Manufacturer changed focus to cell therapy | Drug supply |
| NCT03235934 | Glycemic Impact on Glioblastoma Outcomes | — | withdrawn | Aug 1, 2017 | University Health Network, Toronto | Logistical Issues | Other (stated, no rule matched) |
| NCT01587144 | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ)… | Phase 2 | terminated | Apr 30, 2012 | Spectrum Pharmaceuticals, Inc | Sponsor's decision | Sponsor / business decision |
| NCT01058850 | Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic… | Phase 1 | terminated | Jan 29, 2010 | Paul Graham Fisher | Resources can be better spent on higher enrolling studies | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 21, 2023source: clinicaltrials